Davis Polk partner and White Collar Criminal Defense and Government Investigations Group co-head Angela Burgess will be will be among the speakers at ACI’s 12th Annual Advanced Forum on FCPA & Anti-Corruption for the Life Sciences Industry. Burgess will be a panelist on “The DOJ’s New Corporate Enforcement Policy: An Analysis of Initial Impacts, Results and How Life Sciences Companies Should Assess Risk” panel. Topics discussed will include:

  • How the implications of voluntary self-disclosure have changed in the wake of the new policy
  • How the new corporate enforcement policy is factoring into companies’ decisions on whether or not to self-disclose
  • How companies are evaluating the presumption of declination
  • The enhanced value of cooperation
  • The importance of individual vs. corporate accountability
  • What impact the new corporate enforcement policy could have on potential whistleblowers’ motivation to step forward with an allegation
  • The FCPA guidance’s practical meaning of “aggravating circumstances”
  • The importance and meaning of “recidivism”
  • Eligibility for declination in the case of a previous offense
  • When a previous investigation didn’t result in a penalty but a DPA, declination or other corporate integrity agreement with specific compliance conditions attached

The program will be held June 18-19, 2018, in New York.

For more information, please visit the event website.

Copy link to share post